Industry

iOnctura to Present at ASCO IOA-244 Showing Highly Promising Impact on Overall Survival for Patients With Metastatic and Refractory Uveal Melanoma

13 of 16 metastatic Uveal Melanoma (UM) patients continue in trial with promising overall survival rate at 1 year Excellent safety allowed for chronic administration with no dose alterations, achieving intended pharmacological effect Tregs reduced by IOA-244 in peripheral blood and tumor tissue, supporting mechanism of action GENEVA, Switzerland–(BUSINESS WIRE)–iOnctura SA, a clinical-stage oncology company … [Read more…]

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022

STRASBOURG, France–(BUSINESS WIRE)–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical … [Read more…]

Taro Provides Results for the Year Ended March 31, 2022

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021   The quarter ended March 31, 2022, includes one month’s results from the February 28th acquisition of Alchemee. … [Read more…]

Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings

– ALPN-303 Novel Preclinical Data and Preliminary Phase 1 Data at EULAR – – Davoceticept (ALPN-202) Monotherapy Update and Trials in Progress Poster for Pembrolizumab Combination Study at ASCO – SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today … [Read more…]

4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

– Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months – Study sites are open for patient enrolment LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today … [Read more…]

Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2022 Annual Meeting

NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced three Flatiron-authored abstracts have been accepted for poster discussion and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7. “As demonstrated by our research at ASCO this year, we are at the forefront of our industry to improve patient lives through … [Read more…]

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in combination with immune checkpoint inhibitors. AU-011 is being developed for the treatment of life-threatening cancers … [Read more…]

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

– Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma – CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival … [Read more…]

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

– Results demonstrated an objective response rate of 54% and an overall clinical benefit rate of 91% – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib (CABOMETYX®) in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data … [Read more…]

Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy

First disclosure of results from primary analysis of Phase 2 PILOT study shows Breyanzi delivered complete responses in more than half of patients with refractory or relapsed large B-cell lymphoma after first-line therapy who were not deemed candidates for stem cell transplant PILOT patient-reported outcomes analysis showed treatment with Breyanzi improved health-related quality of life … [Read more…]